A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

Judith E. Karp(Sidney Kimmel Comprehensive Cancer Center), Francis J. Giles(The University of Texas MD Anderson Cancer Center), Ivana Gojo(University of Maryland, Baltimore), Lawrence E. Morris, Jacqueline M. Greer(Sidney Kimmel Comprehensive Cancer Center), Bonny Johnson(Vion Pharmaceuticals (United States)), Mya Thein(Sidney Kimmel Comprehensive Cancer Center), Mario Sznol(Vion Pharmaceuticals (United States)), Jennifer A. Low(National Cancer Institute)
Leukemia Research
July 21, 2007
10.1016/j.leukres.2007.05.003
Cited by 99Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis